PPARD

Across TCGA pan-cancer cohorts, PPARD mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PPARD data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PPARD mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PPARD expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, LUAD, and LSCC are the cancer types where PPARD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.744	0.360	.009	5	view →
LUAD	DFS	Median	II,III,IV	0.810	0.263	.035	3	view →
LSCC	DFS	Median	III,IV	1.000	0.163	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PPARD–GBM (OS)

Open the GBM breakdown →